Exalenz Bioscience Adds Johns Hopkins Health Care & Surgery Center to Its Expanding Roster of U.S. Customers

BreathID® uses advanced breath testing technology to rapidly detect H. pylori infection, which can cause upset stomach and is the primary cause of stomach ulcers

Wilmington, Del (PRWEB) November 10, 2011

Exalenz Bioscience, Inc., a provider of breath testing equipment for the diagnosis and management of digestive system and liver conditions, today announced the installation of its BreathID® System for Helicobacter pylori (H. pylori) detection at the Johns Hopkins Health Care & Surgery Center at Green Spring Station.     

The BreathID® Urea Breath Test System offers a highly accurate, rapid, point-of-care assessment of H. pylori, which infects approximately 25 to 30 percent of the United States population. BreathID delivers results in about 10 minutes – about half the time of competitive devices – making it well suited for point-of-care testing.

H. pylori, a bacterium that can reside in the stomach and small intestine, has been demonstrated to contribute to a variety of conditions, ranging from relatively common symptoms such as dyspepsia and abdominal pain to more severe conditions, including gastritis, ulcers and, in some cases, gastric cancer. Conclusively eradicating H. pylori through treatment depends on an accurate diagnosis of active H. pylori infection.

“Urea breath testing is an accurate non-invasive testing methodology for H. pylori infection and the BreathID System offers advantages of convenience, short test times and ease of use that benefit our physicians and patients,” said Anthony N. Kalloo, M.D., Chief, Division of Gastroenterology and Hepatology at Johns Hopkins.“ The ability to accurately diagnose H. pylori infection and provide immediate treatment reflects our consistent commitment to providing the best tools and most convenient services to our patients.”

Urea breath tests (UBT) are the non-invasive mode of choice for diagnosing H. pylori. According to the American College of Gastroenterology's (ACG) 2007 guidelines, the tests most widely used by U.S. physicians (blood antibody tests) are “no better than a coin toss in predicting active infection.” UBT – and the BreathID System – have been proven to accurately and reliably detect active infection, and their use is supported by the ACG clinical guidelines.

“We are pleased that Johns Hopkins has chosen to utilize the BreathID System as a tool to detect H. pylori infection in its patients,” said Steven Eitan, Chief Executive Officer at Exalenz Bioscience. “We continue to see increasing demand for our rapid, point-of-care diagnostic tool, as physicians are looking for improved accuracy and rapid results.”

About Exalenz Bioscience
Exalenz Bioscience develops and markets medical equipment for breath testing for the purposes of diagnosis and management of digestive system and liver conditions. The company sells the BreathID® System together with proprietary disposable test kits. The BreathID® System has been proven effective for clinical use in identifying the presence of the H. pylori bacteria and is presently undergoing clinical tests for use in the field of liver function, liver cirrhosis, and digestive disturbances. Exalenz holds regulatory approvals in Europe and the U.S. for some of the applications and the company is currently in process of applying for approvals for additional applications.

This news release may contain “forward-looking statements.” Statements in this press release, which are not purely historical, are forward-looking statements including statements concerning the Company's business outlook or future economic performance, anticipated revenues, expenses or other financial items, plans and objectives related thereto, and assumptions or expectations relating to any future events, conditions, performance or other matters. Forward-looking statements are subject to risks, uncertainties and factors including, but not limited to, changing customer demands, changing regulatory requirements, customer acceptance of the Company's products, the impact of competitive products and pricing, dependence on existing management, that technology may not function as expected and general economic conditions. The Company assumes no obligation to update the information in this release.

For more details:
U.S. Contact: Sean Hanlon, Vice President, Marketing, 617-794-6936
Investor Relations Contact: Eran Gabay, Gelbert Kahane, Investor Relations, +972-54-246-7278

###

For the original version on PRWeb visit: http://www.prweb.com/releases/prweb2011/11/prweb8952640.htm